Multipotent luminal mammary cancer stem cells model tumor heterogeneity

Breast Cancer Research

Volumn 17, Issue 1, 2015, Pages

  Bao, Lei ^a   Cardiff, Robert D ^b   Steinbach, Paul ^c   Messer, Karen S ^a,c   Ellies, Lesley G ^c  

^a UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN; HERMES ANTIGEN; PROTEIN P53; TRANSCRIPTOME;

ADIPOCYTE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST ADENOCARCINOMA; BREAST ADENOMA; BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER STEM CELL; CELL DIFFERENTIATION; CELL HETEROGENEITY; CLONAL CELL LINE; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; IN VIVO STUDY; INTRADUCTAL CARCINOMA; LUMINAL BREAST CANCER; LUNG ALVEOLUS CELL; METASTASIS; MOUSE; MULTIPOTENT STEM CELL; MYOEPITHELIUM CELL; NONHUMAN; PROTEIN EXPRESSION; ANIMAL; C57BL MOUSE; CARCINOGENESIS; EXPERIMENTAL MAMMARY NEOPLASM; LUNG TUMOR; METABOLISM; PATHOLOGY; PHYSIOLOGY; SECONDARY; TRANSGENIC MOUSE;

ADIPOCYTES; ANIMALS; CARCINOGENESIS; CELL DIFFERENTIATION; FEMALE; LUNG NEOPLASMS; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE, INBRED C57BL; MICE, TRANSGENIC; MULTIPOTENT STEM CELLS; NEOPLASTIC STEM CELLS; TRANSCRIPTOME; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84944401928     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/s13058-015-0615-y     Document Type: Article

References (40)

1. Molyneux G, Geyer FC, Magnay FA, McCarthy A, Kendrick H, Natrajan R, et al. BRCA1 basal-like breast cancers originate from luminal epithelial progenitors and not from basal stem cells. Cell Stem Cell. 2010;7:403-17.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci U S A. 2003;100:3983-8.
3. Nowell PC. The clonal evolution of tumor cell populations. Science. 1976;194:23-8.
4. Wellings S, Jensen M, Marcum R. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J Natl Cancer Inst. 1975;55:231-74.
5. Diallo R, Schaefer KL, Poremba C, Shivazi N, Willmann V, Buerger H, et al. Monoclonality in normal epithelium and in hyperplastic and neoplastic lesions of the breast. J Pathol. 2001;193:27-32.
6. Anderson WF, Chatterjee N, Ershler WB, Brawley OW. Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat. 2002;76:27-36.
7. Garcia-Closas M, Chanock S. Genetic susceptibility loci for breast cancer by estrogen receptor status. Clin Cancer Res. 2008;14:8000-9.
8. Guy C, Cardiff R, Muller W. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol. 1992;12:954-61.
9. Davie SA, Maglione JE, Manner CK, Young D, Cardiff RD, MacLeod CL, et al. Effects of FVB/NJ and C57Bl/6J strain backgrounds on mammary tumor phenotype in inducible nitric oxide synthase deficient mice. Transgenic Res. 2007;16:193-201.
10. Biswas T, Gu X, Yang J, Ellies LG, Sun LZ. Attenuation of TGF-beta signaling supports tumor progression of a mesenchymal-like mammary tumor cell line in a syngeneic murine model. Cancer Lett. 2014;346:129-38.
11. Shaw FL, Harrison H, Spence K, Ablett MP, Simoes BM, Farnie G, et al. A detailed mammosphere assay protocol for the quantification of breast stem cell activity. J Mammary Gland Biol Neoplasia. 2012;17:111-7.
12. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96.
13. National Center for Biotechnology Information (U.S.): The NCBI handbook. In., 2nd edition. edn. Bethesda (MD): National Center for Biotechnology Information (US),; 2013: 1 online resource. http://www.ncbi.nlm.nih.gov/homologene. Accessed 25 July 2015.
14. Prat A, Parker JS, Karginova O, Fan C, Livasy C, Herschkowitz JI, et al. Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res. 2010;12:R68.
15. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 2012;490:61-70.
16. Tan S. Neighbor-weighted K-nearest neighbor for unbalanced text corpus. Expert Syst Appl. 2005;28:667-71.
17. Barrett T, Wilhite SE, Ledoux P, Evangelista C, Kim IF, Tomashevsky M, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991-995. http://www.ncbi.nlm.nih.gov/geo/
18. Kratochwil K. Organ specificity in mesenchymal induction demonstrated in the embryonic development of the mammary gland of the mouse. Dev Biol. 1969;20:46-71.
19. Pickett PB, Pitelka DR, Hamamoto ST, Misfeldt DS. Occluding junctions and cell behavior in primary cultures of normal and neoplastic mammary gland cells. J Cell Biol. 1975;66:316-32.
20. Zucchi I, Bini L, Albani D, Valaperta R, Liberatori S, Raggiaschi R, et al. Dome formation in cell cultures as expression of an early stage of lactogenic differentiation of the mammary gland. Proc Natl Acad Sci U S A. 2002;99:8660-5.
21. Namba R, Maglione JE, Young LJ, Borowsky AD, Cardiff RD, MacLeod CL, et al. Molecular characterization of the transition to malignancy in a genetically engineered mouse-based model of ductal carcinoma in situ. Mol Cancer Res. 2004;2:453-63.
22. Shackleton M, Vaillant F, Simpson KJ, Stingl J, Smyth GK, Asselin-Labat M-L, et al. Generation of a functional mammary gland from a single stem cell. Nature. 2006;439:84-8.
23. Stingl J, Eirew P, Ricketson I, Shackleton M, Vaillant F, Choi D, et al. Purification and unique properties of mammary epithelial stem cells. Nature. 2006;439:993-7.
24. Tennenbaum T, Belanger AJ, Glick AB, Tamura R, Quaranta V, Yuspa SH. A splice variant of alpha 6 integrin is associated with malignant conversion in mouse skin tumorigenesis. Proc Natl Acad Sci U S A. 1995;92:7041-5.
25. Hollern DP, Andrechek ER. A genomic analysis of mouse models of breast cancer reveals molecular features of mouse models and relationships to human breast cancer. Breast Cancer Res. 2014;16:R59.
26. Herschkowitz JI, Simin K, Weigman VJ, Mikaelian I, Usary J, Hu Z, et al. Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol. 2007;8:R76.
27. Clarke MF, Dick JE, Dirks PB, Eaves CJ, Jamieson CH, Jones DL, et al. Cancer stem cells--perspectives on current status and future directions: AACR Workshop on cancer stem cells. Cancer Res. 2006;66:9339-44.
28. Subramanian A, Tamayo P, Mootha VK, Mukherjee S, Ebert BL, Gillette MA, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005;102:15545-50.
29. Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adelaide J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006;25:2273-84.
30. Lim E, Wu D, Pal B, Bouras T, Asselin-Labat ML, Vaillant F, et al. Transcriptome analyses of mouse and human mammary cell subpopulations reveal multiple conserved genes and pathways. Breast Cancer Res. 2010;12:R21.
31. Symth GK. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol. 2004;3:Article 3.
32. Meyer MJ, Fleming JM, Ali MA, Pesesky MW, Ginsburg E, Vonderhaar BK. Dynamic regulation of CD24 and the invasive, CD44posCD24neg phenotype in breast cancer cell lines. Breast Cancer Res. 2009;11(6):R82.
33. Sheridan C, Kishimoto H, Fuchs RK, Mehrotra S, Bhat-Nakshatri P, Turner CH, et al. CD44+/CD24- breast cancer cells exhibit enhanced invasive properties: an early step necessary for metastasis. Breast Cancer Res. 2006;8(5):R59.
34. Lim E, Vaillant F, Wu D, Forrest NC, Pal B, Hart AH, et al. Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nat Med. 2009;15(8):907-913.
35. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, Lee JS, et al. Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res. 2009;69:4116-24.
36. Smith BA, Shelton DN, Kieffer C, Milash B, Usary J, Perou CM, et al. Targeting the PyMT oncogene to diverse mammary cell populations enhances tumor heterogeneity and generates rare breast cancer subtypes. Genes Cancer. 2012;3:550-63.
37. Damonte P, Hodgson JG, Chen JQ, Young LJ, Cardiff RD, Borowsky AD. Mammary carcinoma behavior is programmed in the precancer stem cell. Breast Cancer Res. 2008;10:R50.
38. Ma J, Lanza DG, Guest I, Uk-Lim C, Glinskii A, Glinsky G, et al. Characterization of mammary cancer stem cells in the MMTV-PyMT mouse model. Tumour Biol. 2012;33:1983-96.
39. Visvader JE, Lindeman GJ. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer. 2008;8:755-68.
40. Santagata S, Thakkar A, Ergonul A, Wang B, Woo T, Hu R, et al. Taxonomy of breast cancer based on normal cell phenotype predicts outcome. J Clin Invest. 2014;124:859-70.